Qian et al., 2025 - Google Patents
The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLCQian et al., 2025
- Document ID
- 1951492435054149136
- Author
- Qian L
- Wu L
- Miao X
- Xu J
- Zhou Y
- Publication year
- Publication venue
- Apoptosis
External Links
Snippet
The treatment of non-small cell lung cancer (NSCLC) remains a critical challenge in oncology, primarily due to the dysfunction and exhaustion of T cells within the tumor microenvironment, which greatly limits the effectiveness of immunotherapy. This study …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | B7-H3 promotes gastric cancer cell migration and invasion | |
| Xia et al. | EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo | |
| Jacoberger-Foissac et al. | CD73 inhibits cGAS–STING and cooperates with CD39 to promote pancreatic cancer | |
| Yu et al. | The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation | |
| CN104857016B (en) | Method for identifying compounds useful in the treatment of cancer | |
| Hao et al. | Phosphodiesterase 3A represents a therapeutic target that drives stem cell–like property and metastasis in breast cancer | |
| Lin et al. | Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression | |
| Gao et al. | CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer | |
| Li et al. | N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1 | |
| Li et al. | TNFR2 deficiency impairs the growth of mouse colon cancer | |
| Shen et al. | ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner | |
| Zhang et al. | HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer | |
| Hu et al. | Enhanced antitumor activity of cetuximab in combination with the Jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes | |
| Zhou et al. | CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells | |
| Lin et al. | circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma | |
| Meidenbauer et al. | Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC | |
| Wen et al. | Clusterin-mediated polarization of M2 macrophages: A mechanism of temozolomide resistance in glioblastoma stem cells | |
| WO2024040148A1 (en) | Combination treatment for cancer | |
| Chang et al. | Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity | |
| Wang et al. | EMP2 acts as a suppressor of melanoma and is negatively regulated by mTOR-mediated autophagy | |
| US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
| Qian et al. | The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLC | |
| CN115515636A (en) | Methods and compositions for treating APC-deficient cancers | |
| JP7510144B2 (en) | Anticancer drugs and their uses | |
| EP3463474A1 (en) | Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer |